Get the Stockscreener App
0.716
4.53%
0.031
After Hours:
.72
0.004
+0.56%
Vincerx Pharma Inc stock is traded at $0.716, with a volume of 117.99K.
It is up +4.53% in the last 24 hours and down -12.68% over the past month.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.
See More
Previous Close:
$0.685
Open:
$0.7189
24h Volume:
117.99K
Relative Volume:
0.63
Market Cap:
$21.45M
Revenue:
-
Net Income/Loss:
$-48.85M
P/E Ratio:
-0.2702
EPS:
-2.65
Net Cash Flow:
$-46.25M
1W Performance:
-0.60%
1M Performance:
-12.68%
6M Performance:
-85.85%
1Y Performance:
-29.11%
1-Day Range:
$0.6804
$0.7262
1-Week Range:
$0.6602
$0.7837
52-Week Range:
$0.5084
$9.3722
Vincerx Pharma Inc Stock (VINC) Company Profile
Name
Vincerx Pharma Inc
Sector
Industry
Phone
650-800-6676
Address
260 SHERIDAN AVENUE, PALO ALTO
Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-14-22 | Initiated | H.C. Wainwright | Buy |
| Dec-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-21 | Initiated | SVB Leerink | Outperform |
| Sep-13-21 | Initiated | Laidlaw | Buy |
| Aug-25-21 | Initiated | B. Riley Securities | Buy |
Vincerx Pharma Inc Stock (VINC) Latest News
Why Is Cancer Focused Penny Stock Vincerx Pharma Trading Higher Today? - MSN
Vincerx Pharma (NASDAQ:VINC) Trading Down 2.1% - Defense World
A better buy-in window may exist right now for Vincerx Pharma Inc (VINC) - SETE News
Investing in Vincerx Pharma Inc (VINC) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely - Simply Wall St
Companies Like Vincerx Pharma (NASDAQ:VINC) Could Be Quite Risky - Yahoo Finance
Vanguard Group Inc. Has $3.38 Million Position in Vincerx Pharma, Inc. (NASDAQ:VINC) - Defense World
Vincerx Pharma Announces Stock Option Repricing and Shareholder Approval - TipRanks
VINC Stock Earnings: Vincerx Pharma Beats EPS for Q2 2024 - MSN
Vincerx Pharma Reports Second Quarter 2024 Financial Results - GlobeNewswire
Vincerx Pharma Reports Second Quarter 2024 Financial Results - StockTitan
Vincerx Pharma Reports Second Quarter 2024 Financial Results - Yahoo Finance
Acadian Asset Management LLC Sells 36,571 Shares of Vincerx Pharma, Inc. (NASDAQ:VINC) - Defense World
Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Decreases By 31.7% - Defense World
How should investors view Vincerx Pharma Inc (VINC)? – US Post News - US Post News
Vincerx Pharma Inc (VINC) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Down 29.3% in June - Defense World
Vincerx Pharma Inc Inc. (VINC) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Vincerx Pharma (VINC) Moves to Buy: Rationale Behind the Upgrade - MSN
Vincerx Pharma (VINC) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Vincerx Pharma (NASDAQ:VINC) Trading Down 7.1% - Defense World
Balance Sheet Insights: Vincerx Pharma Inc (VINC)'s Debt-to-Equity and Long-Term Debt/Eq Ratios – DWinneX - The Dwinnex
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - Investing News Network
Vincerx Pharma to Participate in the Jefferies Virtual Healthcare Conference - The Globe and Mail
Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update - Defense World
Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual ... - The Globe and Mail
Vincerx Pharma Reports First Quarter 2021 Financial Results and Provides a Corporate Update - The Globe and Mail
Vincerx Pharma Announces Completion of Public Warrant Redemption - The Globe and Mail
Market Recap Check: Vincerx Pharma Inc (VINC)'s Negative Finish at 0.68, Up/Down -2.81 – DWinneX - The Dwinnex
Is Vincerx Pharma Inc (VINC) a threat to investors? – US Post News - US Post News
Vincerx Pharma (VINC) Price Target Increased by 10.53% to 7.14 - MSN
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants - Investing News Network
Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday? - MSN
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - Investing.com India
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - The Bakersfield Californian
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants - Investing News Network
Market Update: Vincerx Pharma Inc (VINC) Sees Positive Movement, Closing at 0.84 – DWinneX - The Dwinnex
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants - GlobeNewswire
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants - GlobeNewswire Inc.
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants - GlobeNewswire Inc.
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants - Yahoo Finance
Vincerx Blames Stock Plunge On Overheated ADC Expectations - Scrip
Crude Oil Down Over 1%; Cognyte Software Shares Plummet - Benzinga
Vincerx (VINC) Tumbles on Results From Cancer Therapy Study - Zacks Investment Research
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Benzinga
Dow Dips 150 Points; Laser Photonics Shares Spike Higher - Benzinga
Dow Gains Over 50 Points; Neogen Posts Downbeat Earnings - Benzinga
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket - Benzinga
Vincerx (VINC) Tumbles on Results From Cancer Therapy Study - Yahoo Finance
Vincerx Pharma Inc Stock (VINC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):